Related Experiment Videos
[Pharmacokinetic, bacteriological and clinical studies on cefozopran in children]
Insights
Cefozopran (CZOP) demonstrated 100% clinical efficacy in children with bacterial infections, showing excellent safety with no adverse reactions. This promising antibiotic effectively eradicated common pathogens, supporting its use as a primary treatment.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Bacteriology
Background:
- Bacterial infections pose a significant health concern in pediatric populations.
- Effective and safe antibiotic options are crucial for treating childhood infections.
- Cefozopran (CZOP) is a cephalosporin antibiotic with a broad spectrum of activity.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of cefozopran (CZOP) in pediatric patients.
- To assess the pharmacokinetic profile of CZOP in children.
- To determine the bacteriological eradication rates of common respiratory pathogens.
Main Methods:
- A clinical trial involving 13 pediatric patients with bacterial infections.
- Dosing regimen: 20 mg/kg (or 50 mg/kg for maxillary sinusitis) administered intravenously 3 times daily for 3-11 days.
- Pharmacokinetic analysis included serum concentration and urinary recovery rates; bacteriological assessment involved pathogen identification and eradication.
Main Results:
- 100% clinical efficacy observed in 13 patients (11 pneumonia, 1 otitis media, 1 maxillary sinusitis).
- No adverse reactions or abnormal laboratory findings reported.
- High eradication rates for Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella (Branhamella) catarrhalis, and Haemophilus influenzae.
Conclusions:
- Cefozopran (CZOP) is a highly effective and safe antibiotic for treating acute bacterial infections in children.
- Its favorable pharmacokinetic profile and broad-spectrum activity support its use as a single agent for mild to severe pediatric infections.
- CZOP demonstrates significant potential as a primary therapeutic option in pediatric infectious disease management.
Abstract:
Pharmacokinetic, bacteriological and clinical studies on cefozopran (CZOP) were performed in children. The results were as followed: 1. A total of 13 patients were treated with CZOP. The tested dose was 20 mg/kg (50 mg/kg in maxillary sinusitis), and the drug administered via intravenous bolus injection or 30-minute intravenous drip infusion 3 times daily, for 3-11 days. Clinical efficacies of CZOP in 13 patients with bacterial infections (11 with pneumonia, 1 with otitis media and 1 with maxillary sinusitis) were evaluated as excellent in 13 with an efficacy rate of 100%. Any adverse reactions or abnormal laboratory test results were not observed in any patients. Fourteen causative strains were found in 10 patients. Streptococcus pneumoniae in 4 cases out of 4, Streptococcus pyogenes in 1/1, Moraxella (Branhamella) catarrhalis in 3/3, Haemophilus influenzae in 4/6 were eradicated. 2. Pharmacokinetic studies. The mean serum concentration immediately after intravenous drip infusion over 30-minute of 20 mg/kg was 39.1 micrograms/ml (range: 25.6-52.5 micrograms/ml). The mean urinary recovery rate over 8 hours after administration was 49.0% (range: 45.2-51.8%). Based on the above results and the broad spectrum and great antibacterial activity of CZOP, it is considered that CZOP is a promising antibiotic usable as a single agent for the primary therapy of acute bacterial infections ranging from mild to severe in children.